Skip to content

Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy

Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01815047
Enrollment
85
Registered
2013-03-20
Start date
2012-12-31
Completion date
2019-05-31
Last updated
2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Infection

Keywords

Vitamin D, Pregnancy, Inflammation, Infection, Placenta, Cytokine, Microbiome

Brief summary

The goal of this study is to characterize the function and efficacy of the bioactive nutrient, vitamin D, in relation to infection and inflammatory status across pregnancy. The three specific aims of this study are 1) To address the impact of maternal vitamin D status on inflammation and infections across pregnancy using retrospective data, 2) To address the impact of vitamin D supplementation on maternal vitamin D status, inflammation and infections across pregnancy using prospective data and 3) To assess the impact of maternal vitamin D status during pregnancy on inflammatory mediators at the level of the placenta.

Detailed description

Archived serum collected from 158 adolescents at mid-gestation (approximately 26 weeks) and delivery will be analyzed for inflammatory cytokines. The impact of these inflammatory markers will be assessed by comparing the data to measures of vitamin D (25(OH)D, calcitriol and parathyroid hormone) and infections and inflammatory complications abstracted from medical charts. Placental samples were collected from a subset (n=132) of these pregnant teens and these tissues will be analyzed using genome wide microarray of messenger ribonucleic acid (mRNA) and microRNA (miRNA) related to inflammatory processes. A separate group of pregnant adolescents (n=140) will be recruited at entry into prenatal care for a vitamin D supplementation trial. Teens will be randomly assigned to one of two supplements (200 IU D3/d vs. 2000 IU D3/d). Similar to the retrospective analysis, maternal calciotropic hormones and inflammatory cytokines will be assessed at entry into the study, mid-gestation (23-28 weeks) and at delivery. Inflammatory processes and infections reported across pregnancy will be evaluated in relation to vitamin D status and inflammatory markers.

Interventions

DIETARY_SUPPLEMENTVitamin D3 Supplementation

Sponsors

University of Rochester
CollaboratorOTHER
Cornell University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
13 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Female adolescents between 13 and 18 years of age * Between 12 and \< 30 weeks pregnant

Exclusion criteria

* HIV-infection * Eating disorders * Malabsorption diseases * Diabetes mellitus * Gestational diabetes * Pregnancy induced hypertension or elevated diastolic blood pressure (\>110) * Steroid use * Substance abuse history * Taking medications known to influence Ca or vitamin D status * Diagnosis of elevated blood lead concentrations during childhood * Smokes tobacco

Design outcomes

Primary

MeasureTime frameDescription
Change in Vitamin D status, infections and inflammation across pregnancy after Vitamin D supplementationEntry into study, mid-gestation and deliveryMaternal calciotropic hormones (25(OH)D, 1,25(OH)2D, 24,25(OH)2D, and PTH) and inflammatory cytokines (CRP, interleukin \[IL\]-6 and IL-10 and tumor necrosis factor \[TNF\]-alpha) will be measured at entry into the study and again at 23-28 weeks gestation and delivery after treatment with 200 IU or 2000 IU D3/d. These measures will be compared to inflammatory processes and infections reported in medical records across pregnancy.

Secondary

MeasureTime frameDescription
Change in maternal vitamin D status and inflammatory markers in serumMid-gestation and deliveryIn a retrospective analysis, inflammatory cytokines (CRP, IL- 6 and IL-10 and TNF-alpha) in archived serum collected from a cohort of 158 adolescents that were longitudinally followed across pregnancy both at mid-gestation and at delivery will be related to 25-hydroxyvitamin D (25(OH)D), 1,25- dihydroxyvitamin D (1,25(OH)2D) and parathyroid hormone (PTH) and medically treated infections and inflammatory conditions abstracted from medical records.
Association of maternal vitamin D status (25(OH)D concentration with longitudinal change in 1,25(OH)2D, PTH, 24,25(OH)2D,and the vitamin D metabolite ratioMid-gestation and delivery

Other

MeasureTime frameDescription
Vitamin D and placental inflammationDeliveryGenome-wide microarray studies of mRNA and miRNA in a subset of placental tissue from adolescents with insufficient (\<15 ng/mL) and sufficient vitamin D status (\>30 ng/mL) will be screened for differential regulation of genes and gene networks involved in inflammatory processes.
Vaginal microbiome profileMid to late gestationVitamin D supplementation (200 IU/d D3 and 2000 IU/d D3), dietary intake, 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25 (OH)2D), parathyroid hormone(PTH), inflammatory cytokines (CRP, IL- 6 and IL-10 and TNF-alpha) and infection (from medical records) will be related to vaginal microbiome profile.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026